Search

El 'Atlas of Cancer Mortality in Portugal and Spain 2003–2012', muestra la distribución espacial de la mortalidad municipal por distintos tipos cáncer para el periodo 2003-2012. Ha sido desarrollado por la Unidad de Epidemiología del Cáncer y Ambiental del Centro Nacional de Epidemiología del ISCIII, que forma parte del CIBERESP, y por el Departamento de Epidemiología del Instituto Nacional De Saúde Doutor Ricardo Jorge de Portugal. El estudio de la distribución geográfica del riesgo de fallecer por cáncer es una de las herramientas que se usan en epidemiología para generar hipótesis sobre la posible implicación de factores ambientales en el origen de los tumores. This project is partially supported by research grant from the Spanish Health Research Fund (FIS) of the National Institute of Health Carlos III (ISCIII), Spain (Project PI17CIII/00040: “Spatial distribution of municipal cancer mortality in Spain (SICAMSA)” (“Distribución Espacial de la Mortalidad municipal por CÁncer en ESpaña (DEMOCAES)”). Introduction. Methods. Results: Oesophagus (ICD-10 C15) Stomach (ICD-10 C16) Colorectal (ICD-10 C18–C21) Pancreas (ICD-10 C25) Larynx (ICD-10 C32) Lung (ICD-10 C33–C34) Female Breast (ICD-10 C50) Prostate (ICD-10 C61) Bladder (ICD-10 C67) Leukaemia (ICD-10 C91–C95) References. Annexes: Annex I and Annex II No

Objectives To characterize asymptomatic SARS-CoV-2 infections and develop a symptom-based risk score useful in primary healthcare. Study design and setting 61,092 community-dwelling participants in a nationwide population-based serosurvey completed a questionnaire on COVID-19 symptoms and received an immunoassay for SARS-CoV-2 IgG antibodies between April 27-June 22, 2020. Standardized prevalence ratios for asymptomatic infection were estimated across participant characteristics. We constructed a symptom-based risk score and evaluated its ability to predict SARS-CoV-2 infection. Results 28.7% of infections were asymptomatic (95% CI 26.1-31.4%). Standardized asymptomatic prevalence ratios were 1.19 (1.02-1.40) for men versus women, 1.82 (1.33-2.50) and 1.45 (0.96-2.18) for individuals, Graphical Abstract Image, graphical abstract

Prostate cancer (PCa) is the second most common cancer among men worldwide. Its etiology remains largely unknown compared to other common cancers. We have developed a risk stratification model combining environmental factors with family history and genetic susceptibility. 818 PCa cases and 1,006 healthy controls were compared. Subjects were interviewed on major lifestyle factors and family history. Fifty-six PCa susceptibility SNPs were genotyped. Risk models based on logistic regression were developed to combine environmental factors, family history and a genetic risk score. In the whole model, compared with subjects with low risk (reference category, decile 1), those carrying an intermediate risk (decile 5) had a 265% increase in PCa risk (OR = 3.65, 95% CI 2.26 to 5.91). The genetic risk score had an area under the ROC curve (AUROC) of 0.66 (95% CI 0.63 to 0.68). When adding the environmental score and family history to the genetic risk score, the AUROC increased by 0.05, reaching 0.71 (95% CI 0.69 to 0.74). Genetic susceptibility has a stronger risk value of the prediction that modifiable risk factors. While the added value of each SNP is small, the combination of 56 SNPs adds to the predictive ability of the risk model. Biological samples were stored at the biobanks supported by Instituto de Salud Carlos III- FEDER: Parc de Salut MAR Biobank (MARBiobanc) (), ‘Biobanco La Fe’ () and FISABIO Biobank (), as well as at the Public Health Laboratory of Gipuzkoa, the Basque Biobank, the ICOBIOBANC (sponsored by the Catalan Institute of Oncology), the IUOPA Biobank of the University of Oviedo, and the ISCIII Biobank. SNP genotyping services were provided by the Spanish ‘Centro Nacional de Genotipado’ (CEGEN-ISCIII). We thank all the subjects who participated in the study and all MCC-Spain collaborators. This work was supported by the ‘Acción Transversal del Cancer’, approved by the Spanish Ministry Council on the 11th October 2007, by the Instituto de Salud Carlos III, co-founded by FEDER funds –‘a way to build Europe’ (grants , , , , , , , , , , ,, , , , , , , , , and ). Support was also provided by the Fundación Marqués de Valdecilla (grant ); the Junta de Castilla y León (grant ); the Consejería de Salud of the Junta de Andalucía (); the Conselleria de Sanitat of the Generalitat Valenciana (grant ); the Recercaixa (grant ); the Regional Government of the Basque Country; the Consejería de Sanidad de la Región de Murcia; European Commission grants ; the Spanish Association Against Cancer (AECC) Scientific Foundation; the Catalan Government DURSI (grant ); the Fundación Caja de Ahorros de Asturias; the University of Oviedo; Societat Catalana de Digestologia; and COST action Eucolongene. The authors thank the “Bioinformatics and Research Group in Genetic and Environmental Epidemiology” (BRG-GEE) of the Cancer and Environmental Epidemiology Unit in III Institute of Health (ISCIII), Spain, for their technical scientific support (Group consisting of Pablo Fernández-Navarro (group leader), Mario González-Sánchez (bioinformatic), Javier González-Palacios (bioinformatic)). Sí

Resumen Objetivo: Describir los patrones de distribución geográfica de la incidencia municipal de los tumores más frecuentes en la provincia de Huelva y compararla con la estimada para el conjunto de España. Método: Se calcularon los riesgos relativos (RR) usando el modelo condicional autorregresivo propuesto por Besag, York y Mollié mediante la herramienta INLA, para los años 2007-2011, de las siguientes localizaciones: colon, recto y ano en hombres y en mujeres; tráquea, bronquios y pulmón, próstata y vejiga en hombres; y mama en mujeres. Estos RR se representaron en mapas de coropletas y de isopletas (mediante interpolación por kriging). Resultados: Los RR para cáncer de vejiga en hombres fueron superiores a 1 en todos los municipios, siendo sus intervalos de credibilidad superiores a la unidad en cuatro municipios, destacando la capital con 1,56 (intervalo de credibilidad al 95%:1,30-1,67). Para el cáncer de próstata, las probabilidades a posteriori en 68 de los 79 municipios quedaron por debajo de 0,1. Para el cáncer de pulmón, nueve municipios mostraron intervalos de credibilidad por debajo de la unidad, casi todos en la zona oriental. En las mujeres, los RR para cáncer de mama fueron significativamente superiores en la zona de la capital. Finalmente, las tasas de incidencia provincial de Huelva muestran en general valores próximos a las estimadas para el conjunto de España, destacando las diferencias en cáncer de vejiga en hombres (35% superior) y en cáncer de próstata (30% inferior). Conclusiones: En la provincia de Huelva existe una distribución espacial municipal de la incidencia de cáncer con unos patrones bien definidos para algunas localizaciones tumorales concretas, presentando en general unas tasas de incidencia cercanas a las del territorio nacional. Abstract Objective: To describe the geographic distribution patterns of the municipal incidence of the most common tumours in the Huelva province (Spain) as compared to the estimated incidence for all of Spain. Methods: Relative risk (RR) was computed based on the conditional autoregressive model proposed by Besag, York and Mollié by applying the INLA tool to the cancer data for 2007-2011 for the following tumour locations: colon, rectum and anus (men and women); trachea, bronchia, and lungs, prostate and bladder in men; and breasts in women. The RR was presented in in choropleth and isopleth (with kriging interpolation) risk maps. Results: RR for bladder cancer in men was greater than 1.0 in all municipalities, with confidence intervals over 1.0 in four municipalities; Madrid having a 1.56 RR (95%CI 1.30-1.67). For prostate cancer, a posteriori probabilities were below 0.1 in 68 of the 79 municipalities. For lung cancer, nine municipalities had confidence limits below 1.0, almost all of them in western Spain. For women, the RR for breast cancer was significantly higher in the capital of province area. The cancer incidence rates for the Huelva province were, in general, similar to those estimated for Spain, standing out bladder cancer in men (35% higher) and prostate cancer (30% lower). Conclusions: In the Huelva province, there is a geographical municipal distribution of cancer incidence with well-defined patterns for some specific tumour locations, with overall incidence rates very similar to those in the rest of Spain.